Side-by-side · Research reference

CortagenvsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/35 cited

BHuman-MechanisticAUTO-DRAFTED8/37 cited

Cortagen

Bioregulatory Tetrapeptide · Khavinson-School

TetrapeptideStructure

↓ LPO productsAntioxidant effectKozina 2007

AnimalEvidence level

Injectable · Animal models

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

Cortagen

Epitalon

Primary target

Cerebral cortex tissue — molecular targets under investigation

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007 Anisimov 2004

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

—

Origin

Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

Cortagen

Epitalon

Animal model dose (rat)

Injection protocol (dose not specified in abstracts)

Multiple injections over study period.

—

Avian model dose (chicken)

40-day injection courseKuznik 2008

Compared to epithalon in hypophysectomized and aged birds.

—

Human peripheral nerve study

Therapeutic course (protocol details not provided)

Posttraumatic recovery context — reference cited but not detailed.

—

Evidence basis

Animal mechanistic studies

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Route

Injectable (inferred from animal protocols)

—

Standard dose

—

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Frequency

—

Once daily during a cycle

Lower / starter dose

—

2.5 mg / day

Duration

—

10–20 day cycles, 1–2× per year

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep preferred (pineal alignment)

Half-life

—

Hours (estimated)

04Side Effects & Safety

Parameter

Cortagen

Epitalon

Antioxidant suppression

Suppression of antioxidant activity noted alongside LPO reductionKozina 2007

Mechanism unclear — possible homeostatic adaptation.

—

Immune/hemostasis effects

No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008

Epithalon reversed deficits; cortagen did not.

—

Human safety data

No adverse events reported in peripheral nerve recovery context

Limited detail in available abstracts.

—

Injection site reaction

—

Mild irritation

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Cancer risk

—

Theoretical via telomerase activation in pre-malignant cells

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Antibody formation

—

Not reported

Absolute Contraindications

Cortagen

—

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

Cortagen

—

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

Cortagen

Epitalon

1. Preparation

Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Injection site

Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.

SQ — abdomen preferred. Rotate sites.

3. Timing

Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.

Pre-sleep preferred to align with pineal axis.

4. Storage

Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.